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St. Vincent's University Hospital, Elm Park, Dublin 4, IrelandBiotherapeutics have greatly advanced the world of medicine, and and metabolomics for the analysis of blood and tissue has opened
products such as monoclonal antibodies, fusion proteins and receptor
antagonists have transformed the therapeutic armamentarium for
rheumatic and musculoskeletal diseases (RMD) in the last 20 years. Bi-
ological understanding of a disease can result in novel targeted thera-
peutics, whereas new molecular pathological insights can stem from
observations when patients have responded differently to the same
treatment. Rheumatoid arthritis (RA) provides an excellent example
of the bidirectional nature of translational research involving clinicians
and scientists working in concert with mutual understanding of both
the clinical problem and the scientiﬁc solution. RA biotherapeutics are
effective in many but not all patients, and adverse effects, namely
increased infections, may limit their use. The current challenges for
translational research and biomedicine in RMD/RA therefore focus on
the following issues: (i) early diagnosis, (ii) personalised medicine,
and (iii) assessment of outcome. The unifying theme to these challenges
is the development of biomarkers, as will be evidenced in the next
paragraphs.
There have been signiﬁcant advances in relation to early diagnosis
for RMD over the past 10 years. Clinical awareness and the importance
of an early diagnosis were increased from 1991with the growth of early
arthritis clinics and the application of the 1987 diagnostic criteria for
RA. These classiﬁcation criteria were updated in 2010 with signiﬁcant
changes. A new biomarker for RA – anti-citrullinated antibody (anti-
CCP) –was ﬁrst suggestedwhen citrullinewas described as an essential
antigenic constituent of RA-speciﬁc antibodies (Schellekens et al.,
1998). Anti-CCP antibodies only became widely available commercially
as recently as 2007, and since this time their utility has been expanded
to include both diagnostic and prognostic markers of RA, as they are
recognised to be associated with poor prognosis or outcome as well as
diagnosis (De Rycke et al., 2004). Even more recently, the presence of
anti-CCP and rheumatoid factor antibodies has been described in
some subjects year before they develop the signs or symptoms of the
disease (Rantapää-Dahlqvist et al., 2003). This knowledge has led to a
number of strategic studies exploring treatment options for very early
RA, at a stage that subjects with joint symptoms and positive antibodies
may receive therapy before signs of RA develop. The full implications
of these studies are awaited (Gerlag, 2013).
The concept of personalised medicine is not new, however the
rapid advances in technologies such as genomics, transcriptomics⁎ Corresponding author.
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2352-3964/© 2014 Published by Elsevier B.V.up new horizons in this area in the last few years (Isaacs and
Ferraccioli, 2011). As outlined above, the range of biotherapeutics
now available for the treatment of RMD is extensive, and the key
challenge for translational scientists is to create and validate a strate-
gic approach to the treatment of RA (Ma et al., 2014). Early diagnosis
is only the ﬁrst step, subsets of patients need to be stratiﬁed by a re-
liable biomarker, or more likely a combination of biomarkers, that
will allow treatment decisions to follow an algorithm deﬁned on a
pathological basis, similar to that which has been developed for the
treatment of breast cancer (Perou et al., 2000). For example, it has
been suggested that B-lymphocyte inﬁltrates on immunohistochemis-
try of synovial tissue may be a biomarker of response to therapy with
rituximab in RA patients.
In order to gauge the success or failure of treatments in RMD,
following early diagnosis and strategic patient stratiﬁcation, we need
reliable and feasible outcomemeasures. Amultidisciplinary group of re-
searchers have attempted to reﬁne and develop Outcome MEasures in
Rheumatoid Arthritis Clinical Trials (OMERACT) using a progressive
and well-deﬁned methodology, combining literature review and con-
sensus over the past 20 years (Kirkham et al., 2013). Initially, the focus
of the group was on RA alone; however over time, they have extended
this approach to most RMD and included clinicians, nurses, industry
partners and, possibly most importantly, the patients themselves.
This group was the ﬁrst to identify and validate a synovial tissue bio-
marker –CD68 – to reﬂect synovial pathologic responses in clinical trials
(Smith et al., 2006). It may be relatively easy to deﬁne the patient who
achieves complete remission – no clinical signs or symptoms of disease
activity and no residual damage – but this is unfortunately quite rare.
According to the most recent studies examining the new EULAR/ACR
remission criteria, complete remission may apply to only 10% or less
of treated patients (Balogh et al., 2013).
In conclusion, there are signiﬁcant challenges ahead for clinicians
and scientists engaged in translational research in RMD, and speciﬁcally
in RA. There is, however, signiﬁcant potential for advances to be made,
in particular using modern technologies applied to blood and synovial
tissue samples in subjects with well-deﬁned clinical characteristics
combined in a systems biology analysis.Conﬂicts of Interest
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